RJFSA
XERS icon

Raymond James Financial Services Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Raymond James Financial Services Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,027
Closed -$53K – 3427
2021
Q2 		$53K Buy
+13,027
New +$49.7K ﹤0.01% 3205

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Raymond James Financial Services Advisors's XERS Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Xeris Biopharma Holdings (XERS) in Q3 2021, closing a stake of 13,027 shares — an estimated $53K sold.

Raymond James Financial Services Advisors first reported a position in XERS in Q2 2021 and held it in 1 quarter. The position peaked at $53K in Q2 2021. 70 funds tracked by Wall St. Rank hold XERS as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Xeris Biopharma Holdings position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,027 Xeris Biopharma Holdings shares in Q3 2021, an estimated $53K.
  • Raymond James Financial Services Advisors first reported a position in Xeris Biopharma Holdings in Q2 2021 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Xeris Biopharma Holdings position peaked at $53K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.